EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 391 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival November 6, 2024 Opinion: What should the cancer agenda look like for the new... September 22, 2022 What Cancer Caregivers Should Know About Hospice Care at Home: A... August 31, 2021 Addressing Racial Disparities in Cancer Care: “Your Stories” Podcast May 12, 2022 Load more HOT NEWS T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast... EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients Self-care Isn’t Selfish Zanidatamab Demonstrates Meaningful Clinical Benefit with a Manageable Safety Profile in...
